Hua Medicine Limited
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Hua Medicine Limited sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Hua Medicine Limited: 6 sponsored US clinical trials, 1 recruiting.
Hua Medicine Limited sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus Type II, with 1 trials.
Upper-quartile sponsor footprint
Hua Medicine Limited sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes
NCT07568678
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
NCT06498284
Drug Interaction Study Between Dorzagliatin and Empagliflozin
NCT03790787
Drug Interaction Study Between Dorzagliatin and Sitagliptin
NCT03790839
Human Mass Balance Study of HMS5552 in Healthy Subjects
NCT03158506
Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM
NCT02597400
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
Therapeutic Areas
What is open in the Hua Medicine Limited pipeline
1 recruiting of 6 indexed (17% open); 5 completed (83%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Diabetes Mellitus Type II (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Hua Medicine Limited: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Hua Medicine Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Hua Medicine Limited page
6 registered trials is a research-attention snapshot, not an endorsement of Hua Medicine Limited or any single study.
- 1 of Hua Medicine Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes Mellitus Type II is the condition Hua Medicine Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus Type II trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Hua Medicine Limited pipeline card: 6 registered trials from official public datasets.Report a data error.